Jump to:
Yam Schaal joined Ropes & Gray's corporate department in 2023. During law school, Yam was a student attorney at Cornell’s Immigration Law clinic, where she assisted students and local community members with immigration questions; the Farmworkers’ Rights clinic, where she helped farmers handle employment issues; and the Cornell Estates Practicum, where she drafted wills for residents in need of legal assistance.
Yam was also a notes editor of the Cornell Journal of Law and Public Policy and was the recipient of the Daniel P. Chernoff Prize for her demonstrated academic excellence in intellectual property and patent law.
Experience
- Represented Teva Pharmaceuticals International GmbH in a strategic global licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications.
- Represented Xilio Therapeutics, Inc. in an exclusive global license agreement with Gilead Sciences to develop and commercialize Xilio's tumor-activated IL-12 program, XTX301.
- Represented New Mountain Capital on its partnership with Amerit Fleet Solutions, a premier provider of commercial fleet maintenance and repair services.
- Represented Cadre Holdings, Inc, a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, on a definitive agreement to acquire Carr’s Engineering Limited (excluding Chirton Engineering) and Carr's Engineering (US), Inc. (together the “Engineering Division”), each a subsidiary of Carr’s Group plc, for an enterprise value of £75 million payable in cash at completion.
- Represented Evident in an agreement to sell its Inspection Technologies division to Wabtec Corporation for $1.78 billion.
- Represented HP Inc. in its acquisition of Vyopta, an Austin-based provider of collaboration management solutions, offering analytics and monitoring for large, unified communications and collaboration (UC) networks.
- Represented Genstar Capital in its majority investment in Flourish Research, an NMS Capital portfolio company and leading multi-site clinical trial organization focused on cardiovascular, metabolic, neuroscience, and infectious disease therapeutic areas.